Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. In more than 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of mRNA, to an enterprise with a diverse investigational pipeline of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and rapid speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the approval of one of the earliest and highly effective vaccines to aid in the fight against COVID-19. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of investigational therapeutics and vaccines for various disease areas. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.